Table 2.
Discriminating value of CSF-GFAP and CSF-S100B levels for NMOSD, MS, OND, and NMOSD subgroups.
| Diseases | Biomarker | AUC | Sensitivity (%) | Specificity (%) | Cut-off | 95% CI | p-Value |
|---|---|---|---|---|---|---|---|
| NMOSD vs MS | S100B | 0.839 | 71.4 | 91.7 | 241.4 pg/ml | 0.74-0.94 | <0.001 |
| GFAP | 0.850 | 71.4 | 91.7 | 2.3 ng/ml | 0.75-0.95 | <0.001 | |
| NMOSD vs OND | S100B | 0.823 | 65.3 | 100.0 | 300.2 pg/ml | 0.72-0.92 | <0.001 |
| GFAP | 0.907 | 67.3 | 100.0 | 2.4 ng/ml | 0.83-0.98 | <0.001 | |
| MS vs OND | S100B | 0.450 | 50.0 | 60.0 | 76.5 pg/ml | 0.12-0.66 | 0.661 |
| GFAP | 0.669 | 41.7 | 86.7 | 2.3 ng/ml | 0.11-0.14 | 0.137 | |
| Subgroups of NMOSD patients | |||||||
| AQP4 Ab+ vs MOG Ab+ | S100B | 0.865 | 84.0 | 100.0 | 282.5 pg/ml | 0.74-0.99 | 0.002 |
| GFAP | 0.772 | 72.0 | 100.0 | 6.2 ng/ml | 0.61-0.93 | 0.022 | |
| AQP4 Ab+ vs Seronegative | S100B | 0.587 | 36.0 | 100.0 | 2148.3 pg/ml | 0.41-0.76 | 0.350 |
| GFAP | 0.646 | 68.0 | 62.5 | 10.9 ng/ml | 0.48-0.81 | 0.118 | |
| MOG Ab+ vs Seronegative | S100B | 0.848 | 100.0 | 81.2 | 282.5 pg/ml | 0.68-1.00 | 0.006 |
| GFAP | 0.613 | 100.0 | 50.0 | 6.7 ng/ml | 0.39-0.84 | 0.375 | |
AUC, area under curve; CI, confidence interval; CSF, cerebrospinal fluid; GFAP, glial fibrillary acidic protein; NMOSD, neuromyelitis optica spectrum disorder; MS, multiple sclerosis; OND, noninflammatory neurological diseases; AQP4 Ab+, aquaporin-4 antibody positive NMOSD; MOG-Ab+, myelin-oligodendrocyte glycoprotein antibody positive NMOSD.